Efficacy And Safety Of Bevacizumab In Platinum-Resistant Ovarian Cancer:a Systematic Review

【Objective】To evaluate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of platinum-resistant recurrent ovarian cancer patients.To provide clinical method and evidence-based medicine for the treatment of platinum-resistant recurrent ovarian cancer patients.【Methods】 A computer-based retrieval was performed in databases,such as Pub Med,The Cochrane Library,Embase,Web of Science,CNKI,CBM.VIP,Wan Fang Data and so on,to collect the randomized controlled trials of platinum-resistant recurrent ovarian cancer patients treated with Bevacizumab combined with chemotherapy from the establishment of the database to January 2022.through screening,extracting and conducting literature quality assesssment.Meta analysis was performed using Rev Man5.3 software to analyze the PFS,OS,ORR,DCR and the incidence of drug-related adverse reactions.【Results】 Total of 1213 patients were included through 11 randomized controlled trials.There were 604 cases in the experimental groups and609 cases in the control groups.The results of meta analysis showed that compared with the control group(chemotherapy),the experimental groups(bevacizumab combined with chemotherapy)significantly prolonged the progression free survival(PFS)(HR=0.55,95 % CI:0.47～0.64;P<0.00001)and total survival(OS)(HR=0.72,95 %CI:0.60～0.86;P=0.0003l),and significant improved the objective remission rate(ORR)(RR=1.51,95%CI: 1.35～1.69;P<0.00001)and the disease control rate(DCR)(RR=1.23,95%CI: 1.15～1.30;P<0.00001).For the adverse drug reactions,the bevacizumab combined with chemotherapy groups increased the risk of hypertension,proteinuria and gastrointestinal perforation.While,there was no significant difference between the adverse reaction of gastrointestinal reaction(nausea vomiting and diarrhea),myelosuppression,liver and renal dysfunction,peripheral neuropathy,thromboembolism,bleeding,mucositis and alopecia between two groups.【Conclusion】Bevacizumab combined with chemotherapy can significantly prolonged the PFS,OS and improved the ORR,DCR of platinum-resistant recurrent ovarian cancers,improved clinical outcomes.